Abstract OT2-01-02: The SMILE Study: A phase II trial of onapristone in combination with fulvestrant for patients with ER-positive and HER2-negative metastatic breast cancer after progression on endocrine therapy and CDK 4/6 inhibitors
Kamaraju, Sailaja, Fowler, Amy, Chaudhary, Lubna N., Burkard, Mark, Giever, Thomas, Hegeman, Robert N, Pipp-Dahm, Michele, Cheng, Yee Chung, Lange, Carol, Jorns, Julie M., Stella, Amy, Siddiqui, Nauman, Zurbriggen, Luke, Rajguru, Saurabh, Tarima, Sergey, Sriram, Deepika, Retseck, Janet, Rui, Hallgeir, Sahmoud, Tarek, Wisinski, Kari B.
Published in Cancer research (Chicago, Ill.) (01.03.2023)
Published in Cancer research (Chicago, Ill.) (01.03.2023)
Get full text
Journal Article